Online Message
After receiving your message, our professional team will contact you shortly.
Bispecific Antibody Platform
Viva Biologics boasts extensive experience in the development of bispecific antibodies, with mature technologies encompassing the design, expression, and purification processes. By integrating CADD/AIDD technologies, we are also capable of assisting clients in drugability evaluation, affinity maturation, and patent circumvention for bispecific antibodies. In summary, we are equipped to deliver high-quality, one-stop bispecific antibody development services.Furthermore, Viva Biotech has entered into a license agreement with Lonza to obtain access to Lonza's bYlok® bispecific pairing technology. This access significantly enhances Viva Biotech's capabilities in large molecules by facilitating the design and production of bispecific antibodies. Lonza's bYlok® technology platform effectively addresses the challenge of heavy-light chain mispairing and enhances the production efficiency and quality of bispecific antibodies.
-
Case StudyCase Study - Bispecific Ab
Case Study - Bispecific Ab
Case Study - Bispecific Ab
Case Study - Bispecific Ab Engineering
-
Lonza's bYlok® Bispecific Antibody Platform
The platform offers several advantages, including high expression levels, stability and affinity comparable to monoclonal antibodies, and high recovery rate. Additionally, it comes with a highly cost-effective licensing price.
Fab-ARm EXchange (FAE) BsAB Design
QC Analysis fOr FAE Case
This site uses cookies and your privacy choices are important to us
We use cookies to improve the user experience and to analyze website traffic. By clicking "Accept", you consent to the use of cookies on our website, such as cookies policies.